Gastrointestinal Adverse Events in Hospitalized Patients Following Orthopedic Surgery: Tapentadol Immediate Release Versus Oxycodone Immediate Release.

BACKGROUND Tapentadol has relatively less effect on mu-opioid receptors compared with other opioids. This has the potential to reduce the occurrence of gastrointestinal (GI) adverse drug events (ADEs). OBJECTIVES To compare the GI ADEs during hospitalization between tapentadol immediate release (IR) and oxycodone IR following orthopedic surgeries. STUDY DESIGN Retrospective cohort study. SETTING A major metropolitan tertiary referral hospital in Australia. METHODS Data for adult orthopedic surgery patients receiving postoperative tapentadol IR or oxycodone IR during hospitalization between January 1, 2018 and June 30, 2019, were collected from electronic medical records. The primary outcome was the occurrence of postoperative GI ADEs occurring during hospitalization. This was defined as a composite of nausea, vomiting, or constipation. RESULTS The study cohort included 199 patients. Of these, 99 patients received tapentadol IR and 100 patients received oxycodone IR for postoperative pain during hospitalization. The mean age was 66 ± 12 years, and 111 patients (56%) were women. There was no significant difference between groups on the occurrence of GI ADEs (53% in oxycodone group and 51% in tapentadol group, difference 2%, 95% confidence interval [CI], -11% to 16%; P = 0.777). After adjusting for potential confounders, the use of tapentadol IR was not associated with a significant reduction of GI ADEs (odds ratio, 0.62; 95% CI, 0.32-1.20; P = 0.154). LIMITATIONS This was a single-center study and should be extrapolated with caution. As this was a retrospective study, the accuracy and availability of data were dependent on documentation in electronic medical records. CONCLUSIONS Tapentadol IR is associated with similar GI ADE occurrence compared with oxycodone IR in patients with orthopedic postoperative pain during hospitalization.

[1]  A. Senagore,et al.  Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden , 2019, Journal of pain & palliative care pharmacotherapy.

[2]  H. Wunsch,et al.  Opioid Prescribing After Surgery in the United States, Canada, and Sweden , 2019, JAMA network open.

[3]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[4]  Maree T. Smith,et al.  Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression , 2018, Neuropharmacology.

[5]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[6]  Roger Chou,et al.  Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. , 2016, The journal of pain : official journal of the American Pain Society.

[7]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[8]  A. Lembo,et al.  Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. , 2014, American journal of gastroenterology supplements.

[9]  E. Shipton.  "Moving forward: outlining the plan"-dean's report of the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists. , 2014, Pain medicine.

[10]  N. Rosenthal,et al.  Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study. , 2013, Journal of opioid management.

[11]  C. Rauschkolb,et al.  Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. , 2013, Pain physician.

[12]  C. Hornuss,et al.  Evidence-based analysis of risk factors for postoperative nausea and vomiting. , 2012, British journal of anaesthesia.

[13]  Lehana Thabane,et al.  Femoral Nerve Block Improves Analgesia Outcomes after Total Knee Arthroplasty: A Meta-analysis of Randomized Controlled Trials , 2010, Anesthesiology.

[14]  S. Daniels,et al.  A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain , 2009, Current medical research and opinion.

[15]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[16]  K. Schiene,et al.  (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties , 2007, Journal of Pharmacology and Experimental Therapeutics.

[17]  R. Herings,et al.  In‐hospital use of opioids increases rate of coded postoperative paralytic ileus , 2007, Pharmacoepidemiology and drug safety.

[18]  E. Viscusi,et al.  Tapentadol immediate release for moderate to severe acute post-surgery pain. , 2019, Journal of opioid management.

[19]  S. Daniels,et al.  A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. , 2009, Current medical research and opinion.

[20]  J. Stegmann,et al.  The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery . , 2008, Current medical research and opinion.